Pelvic Neoplasms

Subscribe to Selected New Research on Pelvic Neoplasms

163 relevant articles (7 outcomes, 16 trials/studies) found for this Disease

Description: Tumors or cancer of the pelvic region.

Also Known As:

Cancer of the Pelvis; Neoplasms of Pelvis; Pelvis Cancer; Pelvis Neoplasms; Cancer, Pelvic; Cancer, Pelvis; Cancers, Pelvic; Cancers, Pelvis; Neoplasm, Pelvic; Neoplasm, Pelvis; Neoplasms, Pelvic; Neoplasms, Pelvis; Pelvic Cancers; Pelvic Neoplasm; Pelvis Cancers; Pelvis Neoplasm; Cancer of Pelvis; Pelvic Cancer

Relationship Network

Disease Context: Research Results

Neoplasms: 387640

Neoplasms by Site: 1

Pelvic Neoplasms: 163

Related Diseases

1.	Neoplasms (Cancer)
2.	Carcinoma (Carcinomatosis)
3.	Renal Cell Carcinoma (Grawitz Tumor)
4.	Pelvic Neoplasms
5.	Pain (Aches)

Experts

1.	Constantinides, Constantinos: 1 article (09/2008)
2.	Stolzenburg, Jens-Uwe: 1 article (09/2008)
3.	Liatsikos, Evangelos N: 1 article (09/2008)
4.	Kallidonis, Panagiotis: 1 article (09/2008)
5.	Casey, Rowan G: 1 article (09/2008)
6.	Rabenalt, Robert: 1 article (09/2008)
7.	Maun, Dipen: 1 article (05/2008)
8.	Gorfine, Stephen R: 1 article (05/2008)
9.	Bauer, Joel J: 1 article (05/2008)
10.	Stern, David: 1 article (05/2008)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Pelvic Neoplasms:

1.	ferumoxtran (ultrasmall superparamagnetic iron oxide)IBA 06/01/1998 - "PURPOSE: To evaluate the clinical and biologic safety of ultrasmall superparamagnetic iron oxide particles (AMI-227) as a contrast agent for magnetic resonance (MR) lymphography and to assess their efficacy for the differentiation of metastatic and benign nodes in patients with urologic and pelvic cancer" 06/01/1998 - "CONCLUSION: AMI-227 is safe and may facilitate the differentiation of metastatic and benign nodes in patients with urologic and pelvic cancers." 01/01/1997 - "Fifteen histologically classified lymph nodes in six patients with known primary pelvic cancer (four prostate; one rectum; one uterus) were evaluated with T2-weighted fast spin-echo (FSE) and T2-weighted gradient-echo (GRE) MRI at 1.5T 12 to 48 hours after intravenous administration of Combidex at a dose of 1.7 mg Fe/kg. Quantitative image evaluation was performed by comparing signal intensity of individual nodes on pre- and postcontrast images" Order ALL the reference details at left...*
2.	Technetium Tc 99m Sestamibi (Cardiolite)FDA Link 01/01/2002 - "CONCLUSIONS: (99m)Tc MIBI cannot be recommended for the imaging of pelvic cancer alone, but it may be helpful in the identification of intra-abdominal spread of ovarian carcinoma and appears to offer significant advantages over ultrasound." Order ALL the reference details at left...
3.	Sucralfate (Carafate)FDA LinkGeneric 05/01/1997 - "RESULTS: The results of several studies indicate that sucralfate treatment especially during radiotherapy for pelvic cancer leads to a significant amelioration of clinical symptoms and morphological changes" 08/08/1991 - "Prevention of irradiation-induced bowel discomfort by sucralfate: a double-blind, placebo-controlled study when treating localized pelvic cancer." 06/01/1992 - "Effects of sucralfate on acute and late bowel discomfort following radiotherapy of pelvic cancer." 06/01/1997 - "Clinical trials of intravesical sucralfate seem warranted in patients irradiated for pelvic cancer or with severe cystitis caused by cytotoxic drugs." 06/01/1992 - "Therefore, we investigated the possible effects of sucralfate, an aluminium hydroxide complex of sulfated sucrose used in the treatment of gastric ulcer, in preventing radiation-induced diarrhea and bowel discomfort in patients treated with curative intention for pelvic cancer with external radiotherapy" Order ALL the reference details at left...
4.	PhenacetinIBA 07/01/1986 - "Phenacetin and papillary necrosis: independent risk factors for renal pelvic cancer." 06/15/1982 - "Standardized risk ratios indicated a dose-response relationship for both phenacetin-containing and non-phenacetin analgesics: moderate consumption doubled the risk of renal pelvic cancer, and heavy consumption increased at risk to 6-16 times that for noncomsumers." 01/21/1993 - "This study showed that the risk of renal pelvic cancer was increased by phenacetin/aspirin compound analgesics (RR = 12.2; 95% CI 6.8-22.2) to a far greater extent than by paracetamol (RR = 1.3; 95% CI 0.7-2.4; not significant)" Order ALL the reference details at left...
5.	Amifostine (Ethyol)FDA LinkGeneric 12/01/2002 - "The few clinical trial data available on the use of amifostine in cervical cancer or pelvic cancer patients suggest benefit in reducing treatment toxicity" 12/01/2002 - "In a randomized phase II trial comparing SC amifostine versus no amifostine in 140 patients undergoing radiation therapy for head and neck, thoracic, or pelvic cancers, amifostine treatment was associated with reductions in mucosal toxicity and delays in radiation therapy among the 19 patients with head and neck cancer, as well as in the thoracic and pelvic cancer groups" 12/01/2003 - "The limited available data on the use of amifostine in patients with cervical or pelvic cancers indicate a benefit in reducing chemoradiation toxicity, although cisplatin regimens used in the early investigations in cervical cancer are no longer considered optimal" Order ALL the reference details at left...
6.	Morphine (MS Contin)FDA LinkGeneric 10/01/1981 - "Clinical trials for abatement of intractable pelvic cancer pain were conducted in two patients, each electing surgical implantation of one of two indwelling catheter systems for administration of morphine into the spinal epidural space" 05/01/1986 - "Since December 1984, the authors have used this totally implantable drug delivery system for continuous epidural morphine infusion in two patients who had been suffering from chronic pain caused by pelvic cancer associated with metastatic and/or invasive lesions: Case 1: a 61-year-old man with rectum cancer; and Case 2: a 44-year-old man with colon cancer" Order ALL the reference details at left...
7.	Analgesics (Analgesic Drugs)IBA 06/15/1982 - "Regular consumption of analgesics conferred a tenfold relative risk of renal pelvic cancer in women and in men a risk ratio of 4-8. The fraction of cases for which analgesic consumption was an attributable risk was 0.74 in women and 0.43 in men" 06/15/1982 - "Standardized risk ratios indicated a dose-response relationship for both phenacetin-containing and non-phenacetin analgesics: moderate consumption doubled the risk of renal pelvic cancer, and heavy consumption increased at risk to 6-16 times that for noncomsumers." 01/21/1993 - "This study showed that the risk of renal pelvic cancer was increased by phenacetin/aspirin compound analgesics (RR = 12.2; 95% CI 6.8-22.2) to a far greater extent than by paracetamol (RR = 1.3; 95% CI 0.7-2.4; not significant)" Order ALL the reference details at left...
8.	tranilast (N 5')IBA 05/01/1999 - "SUBJECTS AND METHODS: Nineteen patients with proven primary abdominal or pelvic cancer (prostatic [n = 10]; colonic [n = 5]; endometrial [n = 1]; Merkel cell tumor [n = 1]; lymphoma [n = 1]; seminoma [n = 1]) were enrolled as part of our phase II and phase III clinical trials" 11/01/2005 - "PATIENTS AND METHODS: From november 2001 to august 2002, six patients received trastuzumab for metastatic transitional cell carcinoma of the bladder (n=5) or renal pelvic cancer (n=1)" Order ALL the reference details at left...
9.	erbB-2 Receptor (Receptor, erbB 2)IBA 01/01/1995 - "An immunohistochemical study of the expression of epidermal growth factor receptor (EGFR) and c-erbB-2 protein was performed in fresh-frozen sections from 30 patients with transitional cell cancers (TCCs) of the upper urinary tract (15 renal pelvic cancers, 15 ureteral cancers) who underwent total nephroureterectomy" Order ALL the reference details at left...
10.	Epidermal Growth Factor Receptor (EGF Receptor)IBA 01/01/1995 - "An immunohistochemical study of the expression of epidermal growth factor receptor (EGFR) and c-erbB-2 protein was performed in fresh-frozen sections from 30 patients with transitional cell cancers (TCCs) of the upper urinary tract (15 renal pelvic cancers, 15 ureteral cancers) who underwent total nephroureterectomy" Order ALL the reference details at left...

Therapies and Procedures

1.	Drug Therapy (Chemotherapy) 03/15/1971 - "Better surgical techniques, combined with irradiation and chemotherapy have improved treatment of this pelvic cancer since 1944, but generally significant improvement in the treatment of malignancies has yet to be achieved" 01/01/1995 - "However the introduction of intra arterial pelvic chemotherapy as first line treatment of inoperable pelvic cancer warrants further studies." 08/01/2004 - "Stop-flow technique for loco-regional delivery of high dose chemotherapy in the treatment of advanced pelvic cancers." 05/01/1985 - "Gluteal artery occlusion: intra-arterial chemotherapy of pelvic neoplasms." 07/01/1984 - "Continuous regional arterial chemotherapy with subcutaneous infusional pump in pelvic neoplasms" Order ALL the reference details at left...
2.	Pelvic Exenteration 01/01/1996 - "Further studies are ongoing to evaluate the efficacy of such a neosphincter as continent system for bladder substitution after pelvic exenteration for pelvic cancers." 03/01/2007 - "Total pelvic exenteration (TPE) is a radical and aggressive procedure performed in the local advanced pelvic cancer started from any pelvic organ" 03/01/2007 - "Total pelvic exenteration in the treatment of advanced pelvic cancer]" 09/01/2006 - "Laparoscopic pelvic exenteration for advanced pelvic cancers: a review of 16 cases." 12/01/2002 - "Pelvic exenteration can be proposed to non-metastatic patients with advanced or recurrent pelvic cancer and remains frequently the only potentially curative option in combination with others therapies" Order ALL the reference details at left...
3.	Brachytherapy 11/01/1983 - "Low dose rate (LDR) neutron brachytherapy has been shown to be effective against cervical and advanced pelvic cancers; and produces 5 year cures without a high frequency of normal tissue complications" 01/19/2005 - "Pelvic external radiotherapy with or without brachytherapy plays an important role in the management of pelvic cancers" 10/01/1990 - "Interstitial brachytherapy in pelvic neoplasms]" 05/01/1985 - "Therapeutic dosimetry for Cf-252 neutron brachytherapy of pelvic cancer." 07/01/1983 - "This indicates that a variety of individualized arrangements for different clinical presentations can be used for brachytherapy of gynecological pelvic neoplasm." Order ALL the reference details at left...
4.	Nephrectomy 08/01/1992 - "Possible contributing factors include reduced venous inflow in patients with prior nephrectomy or pelvic neoplasms, pelvic venous compression by tumor mass, and hypercoagulable states." 09/01/1989 - "Right nephrectomy was performed under the diagnosis of either renal pelvic cancer or esophageal cancer metastatic to the kidney" 05/01/1984 - "As treatment, surgery (radical nephrectomy) and anti-cancer chemotherapy were effective in 3 cases (2 renal cell carcinomas and one renal pelvic cancer)" 01/01/1994 - "To assess the value of endothelin-1 (ET-1) as a parameter of renal functional overload and the process of hyperfiltration, urinary excretion of ET-1-like immunoreactivity (U-ET-1) and urinary excretion of other parameters [beta 2-microglobulin (beta 2-MG), N-acetyl-beta-D-glucosaminidase (NAG), albumin (Alb) and 24-hour creatinine clearance (Ccr24)] were measured before, 1, 2 and 7 days after unilateral nephrectomy in 15 patients with unilateral renal lesions (renal cell cancer, renal pelvic cancer, ureteral cancer and renal tuberculosis) and after unilateral adrenalectomy in 5 patients with adrenal lesions" Order ALL the reference details at left...
5.	Cystectomy 10/01/2000 - "Materials and methods The study included 11 cystectomy specimens containing invasive TCC (five from patients who had previously received external-beam bladder radiotherapy, but with recurrent TCC) and three 'normal' bladders removed from patients treated by exenteration surgery for extravesical pelvic cancer" 03/01/1992 - "The case is a 45-year-old female who underwent right total nephroureterectomy and partial cystectomy for renal pelvic cancer" 08/01/2007 - "Two years after the therapy, he underwent left radical nephroureterectomy, cystectomy, urethrectomy and construction of an ileal conduit because of left renal pelvic cancer and severe atrophic bladder" 05/01/2004 - "In a subset of patients with intractable symptoms from incurable pelvic cancer, palliative cystectomy and urinary diversion with intestinal segments may not be feasible" 01/01/1994 - "Tumours disappeared in 18 of 24 patients (75%) in group 2, and in 11 of 14 (79%) in group 3. The rate of disease progression was 6% for all 111 patients: 3% (2/73) for group 1, 17% (4/24) for group 2, and 7% (1/14) for group 3. A total of 16 of the 111 patients (14%) underwent total cystectomy, the respective figures being 7% in group 1, 29% in group 2, and 29% in group 3. Indications for total cystectomy were progression in 7, recurrent multiple tumours in 5, persistent CIS in 2, a contracted bladder in 1, and occurrence of bilateral renal pelvic cancer in 1. Thus, 4 of 6 patients (67%) who had tumours unresponsive to BCG therapy in group 2 demonstrated progression and necessitated total cystectomy" Order ALL the reference details at left...

Best Treatments:
Research Summary Report
on Pelvic Neoplasms

*WARNING* This specific disease subtype has a relatively small number of significant evidence outcomes. You may proceed to order anyway, or go back to the search field and enter a more general type of the target illness. Once your report has been ordered, however, we can't refund the purchase.

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 7 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>